| Project/Area Number |
25670588
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
BABA hideo 熊本大学, 大学院生命科学研究部, 教授 (20240905)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
BABA Yoshifumi 熊本大学, 大学院生命科学研究部, 講師 (20599708)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | ERCC1 / DPD / VEGFA / 大腸癌 / 化学療法 / バイオマーカー / 抗癌剤感受性 / 転移性肝腫瘍 / 大腸癌肝転移 / 抗癌剤感受性関連遺伝子 / 癌関連遺伝子 / LINE-1 |
|---|
| Outline of Final Research Achievements |
Our previous study showed that administering oxaliplatin as first-line chemotherapy increased expression levels of ERCC1and DPD in liver CRC metastases. Second, whether the anti-VEGF monoclonal antibody bevacizumab alters tumoral VEGFA levels is unknown. We conducted this study to validate our previous findings on ERCC1 and DPD, and clarifiy the response of tumoral VEGFA expression to bavacizumab administration. ERCC1 mRNA expression was significantly higher in the chemotherapy group than in the non-chemotherapy group, and were significantly correlated. VEGFA expression level was higher in patients receiving bevacizumab than in those who did not. This study confirmed that first-line oxaliplatin-based chemotherapy increases ERCC1 and DPD expression levels, potentially enhancing chemosensitivity to subsequent therapy. We also found that bevacizumab induces VEGFA expression in tumor cells, suggesting a biologic rationale for extending bevacizumab treatment beyond first progression.
|
